U.S. Markets closed

Mymetics Corporation (MYMX)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0466-0.0002 (-0.43%)
At close: 1:07PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0468
Open0.0466
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0466 - 0.0466
52 Week Range0.0210 - 0.0650
Volume12,600
Avg. Volume95,644
Market Cap14.155M
Beta (5Y Monthly)-0.46
PE Ratio (TTM)N/A
EPS (TTM)-0.0160
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    Mymetics Starts Preclinical Studies with Baylor College of Medicine for Virosome-based Covid-19 Vaccine

    * Mymetics has started a Covid-19 vaccine development project based on Mymetics' virosome vaccine carrier platform, which will evaluate different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based Covid-19 vaccine.

  • ACCESSWIRE

    Mymetics Receives Support for Virosome-based Covid-19 Vaccine Development from European Vaccine Infrastructure Project (Transvac2)

    EPALINGES, SWITZERLAND / ACCESSWIRE / June 11, 2020 / Mymetics Corporation (MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announced today that its subsidiary, Mymetics SA, has received the confirmation to receive access to the European vaccine infrastructure TRANSVAC2 services for the evaluation and development of virosome-based vaccines against Covid-19, the disease caused by SARS-CoV-2. Since April, Mymetics has started the investigation for the rapid development of a Covid-19 virosome-based vaccine and is thereby partnering with leading academic institutions to start evaluating the most suitable antigens.

  • ACCESSWIRE

    Mymetics Reports Successful Preclinical Study Results with COP-Virosomes as Second-Generation Allergy Immunotherapy

    Second-generation Allergen Immunotherapy with COP-virosomes, based on Anergis Contiguous Overlapping Peptides (COP) linked to Mymetics' virosomes were tested by Stallergenes Greer in a therapeutic model of birch pollen allergy. The results showed that a treatment with COP-virosomes was able to cure allergic asthma in birch pollen sensitized mice. EPALINGES, SWITZERLAND / ACCESSWIRE / May 28, 2020 / Mymetics Corporation (MYMX), a pioneer and leader in the research and development of virosome-based vaccines and immunotherapies against life threatening and life disabling diseases, announced today that Stallergenes Greer, a worldwide leader in allergen immunotherapy (AIT) and Anergis, a leader in ultra-fast AIT research and development, reported the results of a joint research study evaluating the effects of the second generation Contiguous Overlapping Peptides (COP) allergen immunotherapy in a therapeutic model of birch allergy, with the aim of shortening the AIT administration schemes.